A brief report on effect of rhG-CSF in treating leukopenia after radio-and chemo-therapy of patients with breast cancer.
- Author:
Tie-Jun WANG
1
;
Lin-Lin LIU
;
Guang-Hui CHENG
;
Xiao-Lan LIU
;
Ya-Qin QU
;
Zhen-Feng WU
;
Chong-Fang ZHANG
Author Information
1. Department of Radiotherapy, The Second Hospital of Jilin University, Changchun 130021, China.
- Publication Type:Clinical Trial
- MeSH:
Adult;
Breast Neoplasms;
therapy;
Combined Modality Therapy;
Female;
Granulocyte Colony-Stimulating Factor;
adverse effects;
therapeutic use;
Humans;
Leukopenia;
drug therapy;
Middle Aged;
Recombinant Proteins
- From:
Journal of Experimental Hematology
2004;12(3):381-382
- CountryChina
- Language:Chinese
-
Abstract:
The study was to observe the effect of rhG-CSF (lishengsu) in treating leukopenia caused by radiotherapy and chemotherapy in patients with breast cancer. 100 cases of breast cancer received modified radical mastectomy were randomized into two groups with the same treatment of one cycle chemotherapy using the protocol of CAF at two weeks after the operations and then radiotherapy. The patients in treated group received rhG-CSF 75 micro g per day s.c. for 5 - 7 days constantly, and additional 3 - 5 days according to leukopenia during radiotherapy. The patients in control group did not receive rhG-CSF during the chemo- and radio-therapy. The results shows that nadir of WBC and neutrophil counts in the treated group was higher than that in control significantly. In conclusion, effect of lishengsu on leucopenia in process of chemotherapy and radiotherapy shows definite therapeutic effect, the side effects are not remarkable.
